Sep-30-20 Downgrade
Wells Fargo
Overweight → Equal Weight
$14 → $9
Jun-17-20 Initiated
Northland Capital
Outperform
$14
Jul-10-19 Resumed
Credit Suisse
Neutral
Mar-27-19 Upgrade
Morgan Stanley
Underweight → Equal-Weight
Feb-25-19 Upgrade
H.C. Wainwright
Sell → Neutral
$14
Jan-24-19 Upgrade
JP Morgan
Underweight → Neutral
Nov-07-18 Downgrade
JP Morgan
Neutral → Underweight
Nov-07-18 Downgrade
Credit Suisse
Outperform → Neutral
Jul-23-18 Initiated
H.C. Wainwright
Sell
$12.50
May-09-18 Downgrade
Morgan Stanley
Equal-Weight → Underweight
Jan-05-18 Downgrade
BofA/Merrill
Buy → Underperform
Dec-06-17 Downgrade
Mizuho
Buy → Neutral
$16
Jul-21-17 Downgrade
JP Morgan
Overweight → Neutral
May-03-17 Initiated
Wells Fargo
Outperform
Apr-07-17 Reiterated
Mizuho
Buy
$21 → $22
Feb-22-17 Reiterated
Barclays
Equal Weight
$13 → $16
Nov-04-16 Reiterated
Mizuho
Buy
$19 → $20
Oct-24-16 Reiterated
Wedbush
Neutral
$10 → $13
Oct-10-16 Reiterated
Mizuho
Buy
$24 → $19
Sep-27-16 Reiterated
WallachBeth
Hold
$15 → $17
Jan-05-21 07:30AM
Dec-05-20 11:32AM
Dec-04-20 08:44AM
Dec-03-20 08:30AM
Nov-30-20 01:39PM
Nov-27-20 12:20PM
08:57AM
08:36AM
Nov-07-20 12:31AM
Nov-06-20 04:01PM
10:00AM
09:43AM
Nov-05-20 07:05PM
04:03PM
04:01PM
02:30PM
09:23AM
Oct-29-20 12:35PM
Oct-22-20 04:01PM
12:33PM
Sep-30-20 11:08AM
Sep-29-20 08:55AM
07:15AM
Sep-27-20 07:33AM
Sep-14-20 10:55PM
Sep-05-20 11:31AM
Sep-02-20 04:00PM
Aug-26-20 12:20PM
Aug-07-20 02:52PM
11:18AM
Aug-06-20 10:45AM
07:00AM
Jul-30-20 12:33PM
Jul-23-20 04:05PM
12:17PM
Jul-21-20 07:00AM
Jul-12-20 07:40PM
Jun-08-20 02:51AM
Jun-05-20 11:31AM
Jun-03-20 09:56AM
09:04AM
08:32AM Thomson Reuters StreetEvents
May-28-20 09:10AM
May-27-20 08:51AM
08:00AM
May-11-20 06:53AM
May-07-20 10:00PM
10:56AM
May-06-20 07:15PM
04:05PM
Apr-29-20 12:34PM
Apr-28-20 04:05PM
Apr-16-20 04:05PM
12:10PM
Apr-10-20 08:49AM
Apr-07-20 03:32PM
Mar-26-20 09:00AM
Mar-14-20 11:30AM
Feb-26-20 04:05PM
Feb-25-20 04:05PM
Feb-20-20 11:13AM Thomson Reuters StreetEvents
Feb-14-20 09:50AM
Feb-13-20 09:45AM
08:48AM
07:00AM
Feb-10-20 12:38PM
10:13AM
Feb-06-20 12:31PM
Jan-30-20 04:05PM
Jan-22-20 09:20AM
Jan-06-20 08:00AM
Jan-02-20 04:01PM
09:35AM
Dec-31-19 08:58AM
Dec-27-19 12:00PM
Dec-26-19 09:00AM
Dec-25-19 11:30AM
Dec-23-19 08:33AM
Dec-19-19 07:34PM
Dec-18-19 09:23AM
Dec-13-19 08:39AM
Dec-10-19 09:15AM
08:33AM
Dec-09-19 10:20AM
Dec-03-19 08:51AM
Nov-29-19 09:39AM
Nov-27-19 08:21AM
Nov-26-19 09:36AM
Nov-22-19 09:48AM
Nov-21-19 12:15PM
Nov-19-19 09:13AM
Nov-11-19 09:21AM
Nov-08-19 09:24AM
08:00AM
Nov-06-19 02:23PM Thomson Reuters StreetEvents
10:36AM
10:20AM
Nov-05-19 04:05PM
Nov-01-19 10:52AM
Oct-31-19 09:05AM
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the Canada and European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated with GI diseases; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, Macau, and Japan, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Boston, Massachusetts.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MCCOURT Thomas A President Dec 14 Option Exercise 9.89 99,988 988,881 421,720 Dec 16 04:49 PM MacDonald Kelly Chief Accounting Officer Dec 04 Option Exercise 9.12 5,639 51,428 98,680 Dec 08 04:01 PM MacDonald Kelly Chief Accounting Officer Dec 04 Sale 12.50 5,639 70,488 93,041 Dec 08 04:01 PM MacDonald Kelly Chief Accounting Officer Nov 11 Option Exercise 9.31 3,561 33,153 96,602 Nov 13 04:02 PM MacDonald Kelly Chief Accounting Officer Nov 11 Sale 11.75 3,561 41,842 93,041 Nov 13 04:02 PM Kilroy Conor SVP, GC & Secretary Nov 09 Sale 10.92 836 9,129 128,833 Nov 10 04:09 PM Consylman Gina SVP, CFO & Treasurer Nov 09 Sale 10.92 1,415 15,452 269,699 Nov 10 04:03 PM Rickard Jason SVP, Chief Operating Officer Nov 09 Sale 10.92 394 4,302 235,382 Nov 10 04:12 PM MacDonald Kelly Chief Accounting Officer Nov 09 Sale 10.92 925 10,101 93,041 Nov 10 04:10 PM MacDonald Kelly Chief Accounting Officer Nov 06 Sale 11.25 1,872 21,060 93,966 Nov 10 04:10 PM MacDonald Kelly Chief Accounting Officer Oct 08 Sale 10.50 22,714 238,497 95,838 Oct 13 04:03 PM McHugh Julie Director Sep 08 Sale 9.77 7,950 77,672 123,107 Sep 09 06:26 PM MacDonald Kelly Chief Accounting Officer Aug 17 Sale 10.14 575 5,831 118,552 Aug 19 04:01 PM Rickard Jason SVP, Chief Operating Officer Aug 17 Sale 10.14 689 6,986 235,776 Aug 19 04:05 PM OLANOFF LAWRENCE S Director Jun 10 Sale 10.06 11,350 114,181 68,629 Jun 12 04:32 PM Rickard Jason SVP, Chief Operating Officer May 11 Sale 10.35 510 5,279 234,580 May 13 05:23 PM MCCOURT Thomas A President May 11 Sale 10.35 1,697 17,564 319,847 May 13 05:22 PM MacDonald Kelly Chief Accounting Officer May 11 Sale 10.35 1,153 11,934 118,147 May 13 05:20 PM Mallon Mark Chief Executive Officer May 11 Sale 10.35 23,206 240,182 501,280 May 13 05:21 PM Kilroy Conor SVP, GC & Secretary May 11 Sale 10.35 716 7,411 128,921 May 13 05:19 PM Mallon Mark Chief Executive Officer Feb 24 Sale 11.25 1 11 303,425 Feb 25 04:45 PM Mallon Mark Chief Executive Officer Feb 21 Sale 11.63 7,983 92,842 303,426 Feb 25 04:45 PM MCCOURT Thomas A President Feb 21 Sale 11.63 4,177 48,579 221,062 Feb 25 04:37 PM MacDonald Kelly Chief Accounting Officer Feb 21 Sale 11.63 3,900 45,357 83,127 Feb 25 04:36 PM Gilbert Halley E Chief Admin Officer & SVP Feb 21 Sale 11.63 15,328 178,265 265,991 Feb 25 04:33 PM Consylman Gina SVP, CFO & Treasurer Feb 21 Sale 11.63 12,501 145,387 202,787 Feb 25 04:31 PM Gilbert Halley E Chief Admin Officer & SVP Jan 31 Option Exercise 10.02 60,000 601,200 341,319 Feb 04 04:02 PM Gilbert Halley E Chief Admin Officer & SVP Jan 31 Sale 12.05 60,000 723,000 281,319 Feb 04 04:02 PM MCCOURT Thomas A President Jan 24 Option Exercise 10.02 20,000 200,400 245,239 Jan 28 04:02 PM MCCOURT Thomas A President Jan 24 Sale 12.71 20,000 254,200 225,239 Jan 28 04:02 PM Currie Mark G Director Jan 23 Option Exercise 9.12 60,000 547,200 609,272 Jan 24 04:43 PM Currie Mark G Director Jan 23 Sale 12.59 60,000 755,400 549,272 Jan 24 04:43 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite